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As  the latest  addition  to  the  sub-strain  speciﬁc  WHO  Reference  Reagents  of  BCG  vaccine,  an  international
collaborative  study  was  completed  to  evaluate  the  suitability  of  a candidate  BCG Moreau-RJ  sub-strain
as  a WHO  Reference  Reagent  of  BCG  vaccine.  This  follows  the recent  replacement  of the  WHO  1st Inter-
national  Reference  Preparation  for BCG  vaccine,  by three  sub-strain  speciﬁc  WHO  Reference  Reagents  of
BCG  vaccine  (Danish  1331,  Tokyo  172-1  and  Russian  BCG-I)  in  order  to complete  the  coverage  of most
predominant  sub-strains  used  for  BCG  vaccine  production  and  distribution  for use  worldwide.  The  study
used  cultural  viable  count  and  modiﬁed  ATP assays  to quantify  the  preparation  and  multiplex  PCR  to
conﬁrm  the  identity  of  the sub-strain.  The  establishment  of  this  WHO  Reference  Reagent  of BCG  vac-
cine  of Moreau-RJ  sub-strain  was  approved  by  the WHO  Expert  Committee  on Biological  Standardization
meeting  in October  2012.  This  preparation  is available  for distribution  by  NIBSC-MHRA,  UK.  The data
from  real-time  stability  monitoring  demonstrated  that  these  Reference  Reagents  of BCG  vaccine  are  very
◦iability
TP
tability
stable  in  storage  condition  at −20 C.  They  serve  as  the  valuable  source  of BCG  Reference  Reagents  for
use  as comparators  (1)  for viability  assays  (such  as  cultural  viable  count  and  modiﬁed  ATP  assays);  (2)
for  in  vivo  assays  (such  as  the  absence  of  virulent  mycobacteria,  dermal  reactivity  and  protection  assays)
in  the  evaluation  of  candidate  TB  vaccines  in non-clinical  models;  (3)  for identity  assays  using molecular
biology  techniques.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Based on the recommendations from international experts in
hree WHO  consultation meetings [1–3] on BCG vaccine, the WHO
st International Reference Preparation (IRP) for BCG vaccine estab-
ished in 1965 has been replaced with sub-strain speciﬁc BCG
eference Reagents (RRs). They are the BCG Danish 1331, Russian
CG-I and Tokyo 172-1 and they are available for distribution from
IBSC-MHRA (http://www.nibsc.org; NIBSC code: 07/270, 07/272,
7/274  respectively) since 2010. These preparations represent
ome of the predominant sub-strains used for BCG vaccine pro-
uction and distribution for use worldwide. Attempts to source the
oreau sub-strain, which would have completed the worldwide
overage, were not successful at the time. The required mate-
ial was subsequently sourced and the candidate preparation was
mpoule-ﬁlled for preserving long-term stability. Reference prepa-
ations are essential to both vaccine manufacturers and National
∗ Corresponding author. Tel.: +44 01707 641473; fax: +44 01707 641054.
E-mail address: mei.ho@nibsc.org (M.M.  Ho).
ttp://dx.doi.org/10.1016/j.vaccine.2014.09.065
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Control Laboratories in order to monitor quality control assay
consistency. They may  also be used as a comparator or refer-
ence in research and pre-clinical studies for the development and
evaluation of new tuberculosis (TB) vaccines. An international col-
laborative study using two independent viability assays and an
identity assay was  carried out to evaluate the content and suit-
ability of this candidate as WHO  RR of BCG vaccine of Moreau RJ
sub-strain.
BCG vaccine is a live attenuated strain of Mycobacterium bovis.
Viability of the bacilli is critical for the stimulation of cellular
immune responses that provide protection against M.  tuberculo-
sis; thus the effectiveness of the BCG vaccine. The cultural viable
count assay is not strictly a measure of potency but it is commonly
used as a surrogate marker for potency of BCG vaccines. In recent
years, a modiﬁed ATP assay has been evaluated and adopted as
an appropriate alternative method for estimating viability of BCG
vaccines [4–7]. The multiplex PCR (mPCR) assay, a molecular biol-
ogy technique, has been introduced as a quality control test for
identity of BCG vaccine [8]. This is a useful method to distinguish
between different sub-strains of BCG that are currently being used
in vaccine production. Speciﬁc regions of BCG, RD1, 2, 8, 14 and 16
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ave been successfully employed to produce a ﬁngerprint that dif-
erentiates between sub-strains. The SenX3-RegX3 mycobacterial
wo-component system (responsible for the virulence and phos-
hate dependant gene expression of M.  tuberculosis) has also been
dentiﬁed as a target site for use in identifying BCG sub-strains [8].
his assay has been successfully evaluated in a collaborative study
s a molecular identity test for different sub-strains of BCG vaccine
9].
As in a previous collaborative study [10], three independent
ethods were used to evaluate the suitability of BCG Moreau-RJ
ub-strain as a WHO  Reference Reagent. Its content was deﬁned as
umber of Colony Forming Units (CFU) and amount of ATP (ng) per
mpoule. Multiplex PCR was used to identify the BCG sub-strain.
he study report was approved by the WHO  Expert Committee on
iological Standardization (ECBS) in October 2012 and this WHO
eference Reagent of BCG vaccine of Moreau RJ sub-strain has been
ade available for distribution since 2013. As these BCG Reference
eagents are live preparations, their stability in terms of viability
as been monitored in NIBSC annually to ensure these prepara-
ions maintain their viability within an acceptable range at time of
istribution.
. Materials and methods
.1.  Study materials
The  BCG vaccine preparation of Moreau-RJ sub-strain was
btained lyophilized and sterile-ﬁlled in ampoules at commer-
ial manufacturing facility with Good Manufacturing Practices
GMP). Five thousand ampoules were generously donated by a
ell-established BCG vaccine manufacturer (Fundacao Ataulpho
e Pavia, Brazil) to WHO. This preparation (NIBSC code: 10/272)
as shipped in dry ice and is stored at −20 ◦C at NIBSC. For
he collaborative study, all BCG samples and ATP standard (Bio-
hema, Sweden), mPCR primer set and DNA base pair markers were
hipped on dry ice and the participants were advised to store them
t −20 ◦C until testing. For real-time stability monitoring, all four
HO BCG RRs of BCG vaccines were used (NIBSC code: 07/270,
7/272, 07/274, 10/272).
.2.  Participants of collaborative study
The BCG Moreau-RJ samples were sent to 16 participants in
3 different countries. These include 7 BCG vaccine manufacturers
nd 9 national control laboratories worldwide. Fifteen of the par-
icipating laboratories agreed to perform the cultural viable count
ssay for the estimation of CFU, 10 agreed to perform the modiﬁed
TP assay and 13 agreed to perform the mPCR assay. All partici-
ants are experienced in cultural viable count assay for lyophilized
CG preparations but familiarity with the modiﬁed ATP and mPCR
ssays is varied. Many of the participants have been involved in a
revious collaborative study which involved the use of these tech-
iques. For this report, a code number was allocated at random
o each participant, not necessarily representing the order of the
articipant list (Appendix I).
.3. Study design and testing protocols
Participants were requested to test 10 ampoules of BCG Moreau-
J vaccine preparation in their established routine in-house method
or the cultural viable count assay, 10 ampoules in the modiﬁed ATP
ssay and 2 ampoules in the mPCR assay.For the cultural viable count assay the study design recom-
ended the 10 ampoules of BCG sample should be tested in at
east two to three independent experiments using different batches
f solid medium preparation. No pooling of reconstituted BCG (2014) 6390–6395 6391
ampoules  was permitted for this study and each ampoule was
tested individually. Three 1:2 serial dilutions (with the optimal
dilution as the middle of the serial dilutions) were prepared from
each reconstituted ampoule. Each diluted suspension was  tested in
triplicate, resulting in three readings per dilution and a total of nine
readings per ampoule. After approximately 21 days incubation at
37 ◦C the average CFU counts were calculated, recorded and sent to
NIBSC for collation and statistical analysis.
Laboratories participating in the modiﬁed ATP assay estimated
the content of ATP in 10 lyophilized BCG Moreau RJ samples fol-
lowing the protocol provided. The 10 ampoules of BCG were tested
in at least two to three independent experiments, as in the cultural
viable count assay. Lyophilized BCG samples were reconstituted
with 1 ml  Dubos medium (SSI Diagnostica, Denmark) or other suit-
able culture medium; and the BCG suspensions were incubated at
37 ◦C for 22–26 h. Three 1:2 serial dilutions were prepared from
each overnight BCG culture in pre-warmed medium (undiluted, 1:2
and 1:4). The procedures of ATP extraction and estimation were the
same as described previously [10]. Results were recorded and data
sent to NIBSC for collation and statistical analysis.
Participants were requested to use their own in-house method
to extract and purify DNA from two  ampoules of BCG Moreau-RJ
samples to be used in two  independent mPCR assays. The mPCR
assay protocol was provided to all participants and as described
previously [9]. Horizontal gel electrophoresis was used to resolve
the PCR products. A 50 bp DNA ladder was  used as a marker on
the gel. The PCR product proﬁles were visualized using the partici-
pants’ in-house method and electronic images were sent to NIBSC
for collation and analysis.
2.4.  Stability studies – thermal and real-time
The cultural viable count assay was used to monitor the thermal
stability of the live BCG vaccine preparation and was  performed at
NIBSC only. An accelerated degradation study was  not used for this
live preparation as incubation temperatures greater than 37 ◦C for
a period longer than 4 weeks can kill most of the live bacilli in the
preparation. A slightly modiﬁed method used for temperature sta-
bility, as stated in both WHO  Recommendations [4] and European
Pharmacopoeia monograph for BCG vaccine, freeze-dried [5] was
used instead to determine the thermal stability of the lyophilized
BCG vaccine preparation. Five ampoules each of the BCG Moreau-RJ
preparation were incubated at 4 ◦C or 37 ◦C for a period of 4 weeks
prior to performing the cultural viable count assay. These results
were then compared with those from ampoules stored at −20 ◦C as
recommended storage temperature for this preparation.
Real-time stability study is performed by NIBSC. The viability in
terms of CFUs in cultural viable count assay of all four Reference
Reagents of BCG vaccine stored at −20 ◦C, will be monitored for 10
years of shelf life annually to ensure the viability of these Reference
Reagents is maintained within the acceptable range (as estimated
from collaborative studies) at time of distribution.
2.5. Statistical analysis
All  of the results from the cultural viable count assay were
converted to CFU per ampoule. The mean CFU per ampoule was
calculated from the mean estimates of the colony counts of each
dilution [10] following the WHO/TB/Technical Guide/77.9 (in vitro
assays of BCG products, unpublished working document in 1977).
The choice of formula reﬂects the appropriate weight given to the
number of colonies counted for a test BCG sample at each dilution
level. Any of the ampoules within a laboratory’s results that were
found to be outliers using an in-house program [11] and Grubbs’
test [12] were excluded from further statistical analysis.
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The  mean CFUs in thermal stability study were 10.80 (SD
2.84), 9.90 (SD 0.96) or 3.67 (SD 0.82) million per ampoule when
this lyophilized preparation was  stored at −20 ◦C, 4 ◦C or 37 ◦C,ig. 1. The distribution of CFU counts per ampoule of BCG Moreau-RJ sub-strain
reparation  performed in participating laboratories, excluding one outlier from
aboratory 7.
For the modiﬁed ATP assays, standard curves were generated
y linear regression of log10 light emission reading (response)
n log10 concentration of ATP standard. Responses for the test
mpoules were converted to pmol ATP/100 l using the ﬁt-
ed regression lines. The results were then converted to ng
TP/ampoule.
The overall mean of laboratory means was calculated as the
nal estimate for the preparation for both the cultural viable count
nd modiﬁed ATP assays. An estimate of uncertainty combining the
tandard deviation (SD) of the mean (reﬂecting variability between
aboratories) with the pooled laboratory SD (reﬂecting between-
mpoule homogeneity and variability between assays) was used to
alculate an expanded uncertainty corresponding to a 95% level of
onﬁdence.
. Results
.1. Cultural viable count assay for estimation of CFU
Sixteen complete data sets were received from 15 participants.
able 1 summarizes the mean CFU of the Moreau-RJ sub-strain
reparation, SD and coefﬁcient of variation (CV) of individual
mpoule estimates for each laboratory and the type of solid culture
edia used. Two sets of data (6a and b) were provided from Labora-
ory 6 as two different culture media were used for the viable count
ssay. Data from one ampoule within Laboratory 7 was  excluded
s an outlier using Grubbs’ test [12] and was not used in further
nalysis. Data obtained from Laboratory 3 was omitted from this
tudy as only mean CFU estimates were provided, there was no
nformation on which solid media had been used and no optimal
ount ‘ω’ value for their cultural viable count assay was given.
he distribution of mean CFU from all 10 ampoules of the BCG
reparation performed by each participating laboratory is shown
n Fig. 1.
.2.  Modiﬁed ATP assay for estimation of ATP content
Ten data sets were received from the participants. Details of
he modiﬁed ATP assay conditions used by participating laborato-
ies in this study are listed in Table 2. Results from two  ampoules
ithin Laboratory 11 were excluded as outliers as they were greater
han seven-fold higher than the mean result obtained for the other
mpoules. Table 2 also shows the mean ATP content for the BCG
oreau-RJ preparation (ng/ampoule), SD and CV of the 10 indi-
idual ampoule estimates for each laboratory. The results from
aboratories 5, 7 and 11 were shown to be signiﬁcantly differentFig. 2. The distribution of ATP content of BCG Moreau-RJ sub-strain preparation
performed  in participating laboratories, excluding two outliers from Laboratory 11.
(higher) from those of the other participants by analysis of vari-
ance using Duncan’s multiple comparisons tests. Fig. 2 shows the
distribution of ATP content of the BCG preparation performed in
participating laboratories, excluding two  outliers from Laboratory
11.
3.3. Multiplex PCR assay for identiﬁcation
Thirteen participants returned mPCR results for the BCG
Moreau-RJ preparation. A diluted (1:10) DNA extraction was  rec-
ommended in the study protocol as sometimes the mPCR reaction
of neat DNA extracted from lyophilized BCG vaccine results in
PCR products that are too intense to resolve clearly in gel elec-
trophoresis. This was  not a problem in the present study. The ﬁve
mPCR products from BCG Moreau-RJ sub-strain are expected as RD8
(472 bp), RD2 (315 bp), senX3-regX3 (276 bp), RD14 (252 bp), and
RD1 (196 bp). Each participating laboratory successfully resolved
all ﬁve mPCR products, presented in Fig. 3. The resolution of the gel
image from Laboratory 14 was not as clear as the others. Ten par-
ticipants had extracted and performed subsequent mPCR from two
ampoules of the preparation. Laboratories 1 and 16 returned results
from only one ampoule. Laboratory 2 had combined the contents
of the ampoules prior to the extraction of the DNA.
3.4. Stability studyFig. 3. The multiplex PCR ﬁngerprints of BCG Moreau-RJ sub-strain preparation
performed  in participating laboratories as numbered.
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Table  1
Summary of results of cultural viable count assays from participating laboratories using various solid culture media. The mean content of BCG Moreau-RJ sub-strain preparation
is  presented as million CFU/ampoule.
Laboratory Culture medium used Mean SD CV
1 Middlebrook 11.71 2.26 19.3%
2  Löwenstein–Jensen 3.47 0.72 20.9%
4  Löwenstein–Jensen 10.36 1.34 12.9%
5  Ogawa 1.91 0.53 27.5%
6a  Löwenstein–Jensen 6.29 1.89 30.1%
6b  Middlebrook 3.90 1.26 32.4%
7  Dubois oleic acid 8.64 1.42  16.5%
8  Löwenstein–Jensen 6.70 0.51 7.6%
9  Ogawa 8.84 2.74 31.0%
10  Löwenstein–Jensen 8.73 1.72 19.7%
11  Löwenstein–Jensen 7.66 0.66 8.6%
12  Löwenstein–Jensen 5.55 1.17 21.0%
13  Löwenstein–Jensen 2.42 1.12 46.2%
14 Ogawa 5.04 1.62 32.1%
15  Löwenstein–Jensen 7.38 1.03 14.0%
16  Ogawa 5.54 0.50 9.1%
Mean  6.51
SD  of mean 0.72 (11.1%)
Pooled  between-ampoule SD 1.44 (22.1%)
Combined  uncertainty 1.60 (24.6%)
Expanded  uncertainty (95% conﬁdence) 3.10–9.92
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Fig. 4. Trend monitoring of real time stability data of WHO  Reference Reagents of
T
S
Key: SD, standard deviation; CV, coefﬁcient of variation.
espectively. The % survival in CFU of the preparation from the
hermal stability study was calculated by comparing it with the
ean CFU of preparation stored at −20 ◦C. The % survival at 4 ◦C
as 84.35% and at 37 ◦C was 33.98%.
In  real-time stability, the lower limits of CFU of these RRs are
stimated from the expanded uncertainty (95% conﬁdence) of this
nd previous collaborative studies on cultural viable count [10] and
re 3.37, 29.60, 0.95 or 3.10 million per ampoule for Danish 1331,
okyo 172-1, Russian BCG-I or Moreau-RJ, respectively. The trend
f real time stability collected up to early 2014 is shown in Fig. 4.
he current CFU results in 2014 of all four RRs are above the lower
imits of the acceptable range, as 4.32, 36.56, 4.01 or 7.27 million per
mpoule for Danish 1331, Tokyo 172-1, Russian BCG-I or Moreau-
J, respectively.
.  DiscussionAs in a previous collaborative study, two methodologies (cul-
ural viable count and modiﬁed ATP assays) were used to assess
he content of the BCG Moreau-RJ Reference Reagent preparation.
he results estimated that there are 6.51 million CFU per ampoule
BCG vaccine of various sub-strains of (a) Danish 1331 ,  (b) Tokyo 172-1 ,
(c)  Russian BCG-I , and (d) Moreau-RJ , using the cultural viable count
assay.
able 2
ummary of variations in key experimental steps and results of modiﬁed ATP assay from participating laboratories. The mean ATP content is presented as ng/ampoule.
Laboratory Culture medium
used
No.  of ampoules
tested per
experiment
Samples  prepared
per  ampoule
Luminescence
readings per
sample
Mean  SD CV
1 7H9 1 or 3 3 3 7.06 1.76 24.9%
2  Dubos 1, 2 or 3 3 3 18.03 5.31 29.4%
4  Sauton 10 3 1 9.88 2.40 24.3%
5  7H9 2 3 3 75.68 12.54 16.6%
7  Dubos 3 or 4 3 3 32.42 8.77 27.0%
8  Dubos 5 3 3 8.97 2.02 22.5%
9  7H9 1 or 3 3 3 7.37 1.49 20.2%
10  Dubos 2 3 3 18.38 6.57 35.8%
11  Dubos 5 1 1 56.06 15.36 27.4%
13  Dubos 2 or 3 3 3 13.07 4.93 37.7%
Mean  24.69
SD  of mean 7.41 (30.0%)
Pooled  between-ampoule SD 6.97 (28.2%)
Combined uncertainty 10.18 (41.2%)
Expanded uncertainty (95% conﬁdence) 1.67–47.71
ey: SD, standard deviation; CV, coefﬁcient of variation.
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ith a SD of 0.72; and 24.69 ng ATP per ampoule with a SD of 7.41
or this preparation. There was a broad distribution of the mean CFU
esults received from all participants (Fig. 1). The expanded uncer-
ainty (95% conﬁdence) for this preparation is 3.10–9.92 million.
he cultural viable count CFU results of lyophilized BCG prepara-
ions are usually variable and the data from this study are expected,
specially participants’ own in-house routine cultural viable count
ssay with different solid media and culturing methodologies were
sed. The CV in each participating laboratory also had a wide range
rom 7.6% to 46.2% (Table 1).
There were large differences in the distribution of the mean ATP
ng) content obtained from all participants as shown in Table 2.
he expanded uncertainty (95% conﬁdence) for this preparation
s 1.67–47.71 ng/ampoule. The CV in each participating laboratory
anged from 16.6% to 37.7%. This high variability of the modiﬁed
TP results was similar to the previous study [10]. The dilution
ffect of samples gave inconsistent results leading to only the
TP contents from neat reconstituted samples being used in the
stimation of the mean ATP content in this BCG preparation. The
esults of CFU and ATP content were compared directly. This col-
aborative study clearly demonstrated that the modiﬁed ATP assay
as not an improved method in terms of providing more consis-
ent estimation of the viability in a lyophilized BCG preparation
hen compared with the cultural viable count assay. Some of the
articipating laboratories have limited experience in performing
his ATP assay and this may, in part, contribute to the high vari-
bility of the results. However, this assay remains a rapid method
or estimating the viability of lyophilized BCG preparations and
as been validated for quality control testing in one of the par-
icipating laboratories [6]. There was good agreement of results
or the mPCR assay for identiﬁcation of this BCG sub-strain. All
articipating laboratories of this assay returned the expected ﬁn-
erprints of ﬁve PCR products for the BCG Moreau-RJ sub-strain
nalyzed in the study (Fig. 3). This demonstrates that this assay is
n effective and robust method to conﬁrm the identity of a BCG
ub-strain.
The establishment of WHO  Reference Reagent of BCG vaccine
f Moreau-RJ sub-strain was approved by WHO  ECBS in October
012 with a content of 6.51 million CFU or 24.69 ng ATP per
mpoule. This Reagent (NIBSC code: 10/272) is available and dis-
ributed by NIBSC-MHRA, UK. All the Reference Reagents of BCG
accine are stored in a −20 ◦C facility with a trend monitoring
ystem. The real-time stability of these Reference Reagents is mon-
tored annually to ensure the viability of the content is within an
cceptable range. The data collected in the ﬁrst few years demon-
trated that these Reference Reagents of BCG vaccine are very
table when stored at −20 ◦C. The intended uses of these Reference
eagents are as comparators (1) for viability assays (such as cul-
ural viable count and modiﬁed ATP assays); (2) for in vivo assays
such as the absence of virulent mycobacteria, dermal reactivity
nd protection assays) in the evaluation of candidate TB vaccines in
on-clinical models; (3) for identity assays using molecular biology
echniques.
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